α-Vitamin E (Synonyms: (+)-α-Tocopherol; D-α-Tocopherol)

Name: α-Vitamin E
Brand: MedChemExpress
SKU: HY-N0683
Rating: 5.0 (14 reviews)

Cat. No.: HY-N0683 Purity: 98.88%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

α-Vitamin E ((+)-α-Tocopherol), a naturally occurring vitamin E form, is a potent antioxidant.

For research use only. We do not sell to patients.

α-Vitamin E Chemical Structure

CAS No. : 59-02-9

Size	Price	Stock	Quantity
Liquid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 73	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 73	In-stock	Estimated Time of Arrival: December 31
Liquid
100 mg	USD 66	In-stock	Estimated Time of Arrival: December 31
1 g	USD 92	In-stock	Estimated Time of Arrival: December 31
5 g		Get quote
10 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 14 publication(s) in Google Scholar

Other Forms of α-Vitamin E:

14 Publications Citing Use of MCE α-Vitamin E

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

α-Vitamin E ((+)-α-Tocopherol), a naturally occurring vitamin E form, is a potent antioxidant^[1]^[2].

IC₅₀ & Target

Human Endogenous Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
Erythrocyte	IC₅₀	3.658 μg/mL Compound: alpha-tocopherol	Antioxidant activity in rat erythrocytes assessed as inhibition of phenyl hydrazine-induced haemolysis after 1 hr Antioxidant activity in rat erythrocytes assessed as inhibition of phenyl hydrazine-induced haemolysis after 1 hr	[PMID: 23395966]
Fibroblast	EC₅₀	> 500 nM Compound: alpha-TOH	Inhibition of erastin-induced cell death in FRDA patient-derived fibroblast assessed as depletion of cellular ATP incubated for 12 hrs followed by erastin stimulation and measured after by luciferase-linked ATPase enzymatic assay Inhibition of erastin-induced cell death in FRDA patient-derived fibroblast assessed as depletion of cellular ATP incubated for 12 hrs followed by erastin stimulation and measured after by luciferase-linked ATPase enzymatic assay	[PMID: 33214825]
Fibroblast	GI₅₀	≥ 300 μM Compound: 2, Vitamin E	Growth inhibition of human FRDA primary patient fibroblasts after 48 hrs by calcein-AM-based cell viability assay Growth inhibition of human FRDA primary patient fibroblasts after 48 hrs by calcein-AM-based cell viability assay	[PMID: 22137789]
Fibroblast	EC₅₀	234 nM Compound: 2, Vitamin E	Cytoprotective activity against BSO-induced human FRDA primary patient fibroblasts compound pretreated 12 hrs prior to BSO-induction measured after 48 hrs by calcein-AM-based cell viability assay Cytoprotective activity against BSO-induced human FRDA primary patient fibroblasts compound pretreated 12 hrs prior to BSO-induction measured after 48 hrs by calcein-AM-based cell viability assay	[PMID: 22137789]
HepG2	IC₅₀	> 300 μM Compound: alpha-TOH	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27344490]
HL-60	IC₅₀	255 μM Compound: Vitamin E	Antioxidant activity against TPA-induced ROS production in human HL60 cells by 2',7'-dichlorodihydrofluorescein diacetate cellular-based assay Antioxidant activity against TPA-induced ROS production in human HL60 cells by 2',7'-dichlorodihydrofluorescein diacetate cellular-based assay	[PMID: 12762791]
J774	IC₅₀	> 500 μM Compound: 1	Cytotoxicity against mouse J774 cells by MTT assay Cytotoxicity against mouse J774 cells by MTT assay	[PMID: 17627828]
Lymphocyte	EC₅₀	> 500 nM Compound: alpha-TOH	Anti-ferroptotic activity in FRDA patient-derived Lymphocyte assessed as reduction in RSL3-induced lipid peroxidation incubated for overnight followed by RSL3 stimulation and measured after 90 mins by FACS analysis Anti-ferroptotic activity in FRDA patient-derived Lymphocyte assessed as reduction in RSL3-induced lipid peroxidation incubated for overnight followed by RSL3 stimulation and measured after 90 mins by FACS analysis	[PMID: 33214825]
MCF7	IC₅₀	> 300 μM Compound: alpha-TOH	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27344490]
MT4	IC₅₀	165 μM Compound: alpha-TOH	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27344490]
RPMI-8226	IC₅₀	> 300 μM Compound: alpha-TOH	Cytotoxicity against human RPMI8226 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human RPMI8226 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27344490]
THP-1	IC₅₀	> 500 μM Compound: 1	Cytotoxicity against human THP1 cells by MTT assay Cytotoxicity against human THP1 cells by MTT assay	[PMID: 17627828]
U-937	IC₅₀	100 μM Compound: alpha-TOH	Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27344490]

In Vitro

α-Vitamin E ((+)-α-Tocopherol) is a peroxyl radical scavenger. The importance of this function is to maintain the integrity of long-chain polyunsaturated fatty acids in the membranes of cells and thus maintain their bioactivity^[1].
α-Vitamin E ((+)-α-Tocopherol) has been described to inhibit PKC in various cell types with consequent inhibition of platelet aggregation, endothelial cell nitric oxide production and superoxide production in neutrophils and macrophages. α-Vitamin E ((+)-α-Tocopherol) exposure induced the activation of both the MAP kinase and PI3 kinase (PI3K) pathways, suggesting that it is the oxidative stress that up-regulates kinase pathways and the antioxidant action of α-tocopherol protects the cell membrane fatty acids^[1].
α-Vitamin E ((+)-α-Tocopherol) has proposed benefits for influenza virus A infection, as well as possible activity against hepatitis B and C. α-Vitamin E shows proviral effects, particularly in HEK293T/17 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

α-Vitamin E ((+)-α-Tocopherol) prevents the increase in the pro-inflammatory cytokines IL-1, IL-6, and IFN-γ mRNA and protein compared with the ischemic-reperfused myocardium from untreated pigs and compared to the non-injured area^[1].
α-Vitamin E (D-α-Tocopherol; intraperitoneal injection or oral administration) treatment induces an amelioration of diabetic nephropathy in mice through the activation of diacylglycerol kinase α (DGKα) and the prevention of podocyte loss^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

430.71

Formula

C₂₉H₅₀O₂

CAS No.

59-02-9

Appearance

Liquid (Density: 0.95 g/cm³)

Color

Colorless to light yellow

SMILES

OC1=C(C)C(C)=C2C(CC[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)O2)=C1C

Structure Classification

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (232.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 100 mg/mL (232.17 mM; Need ultrasonic)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3217 mL	11.6087 mL	23.2175 mL
5 mM	0.4643 mL	2.3217 mL	4.6435 mL
10 mM	0.2322 mL	1.1609 mL	2.3217 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 11.25 mg/mL (26.12 mM); Clear solution

This protocol yields a clear solution of ≥ 11.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (112.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: 11.25 mg/mL (26.12 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 11.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (112.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 11.25 mg/mL (26.12 mM); Clear solution

This protocol yields a clear solution of ≥ 11.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (112.5 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 4

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 5

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (5.80 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 6

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 10 mg/mL (23.22 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: ≥99.0%

Select Batch:

Data Sheet (272 KB) SDS (394 KB)

COA (242 KB)

Handling Instructions (2659 KB)

References

[1]. Maret G Traber, et al. Vitamin E, antioxidant and nothing more. Free Radic Biol Med. 2007 Jul 1;43(1):4-15. [Content Brief]

[2]. Daiki Hayashi, et al. Amelioration of diabetic nephropathy by oral administration of d-α-tocopherol and its mechanisms. Biosci Biotechnol Biochem. 2018 Jan;82(1):65-73. [Content Brief]

[3]. Atchara Paemanee, et al. Screening of melatonin, α-tocopherol, folic acid, acetyl-L-carnitine and resveratrol for anti-dengue 2 virus activity. BMC Res Notes. 2018 May 16;11(1):307. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / Ethanol	1 mM	2.3217 mL	11.6087 mL	23.2175 mL	58.0437 mL
	5 mM	0.4643 mL	2.3217 mL	4.6435 mL	11.6087 mL
	10 mM	0.2322 mL	1.1609 mL	2.3217 mL	5.8044 mL
	15 mM	0.1548 mL	0.7739 mL	1.5478 mL	3.8696 mL
	20 mM	0.1161 mL	0.5804 mL	1.1609 mL	2.9022 mL
	25 mM	0.0929 mL	0.4643 mL	0.9287 mL	2.3217 mL
	30 mM	0.0774 mL	0.3870 mL	0.7739 mL	1.9348 mL
	40 mM	0.0580 mL	0.2902 mL	0.5804 mL	1.4511 mL
	50 mM	0.0464 mL	0.2322 mL	0.4643 mL	1.1609 mL
	60 mM	0.0387 mL	0.1935 mL	0.3870 mL	0.9674 mL
	80 mM	0.0290 mL	0.1451 mL	0.2902 mL	0.7255 mL
	100 mM	0.0232 mL	0.1161 mL	0.2322 mL	0.5804 mL

α-Vitamin E Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

α-Vitamin E59-02-9(+)-α-Tocopherol D-α-TocopherolBacterialInfluenza VirusReactive Oxygen SpeciesFerroptosisEndogenous MetaboliteAntioxidantperoxylradicalscavengerInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

α-Vitamin E (Synonyms: (+)-α-Tocopherol; D-α-Tocopherol)

Customer Review

Other Forms of α-Vitamin E:

α-Vitamin E Related Antibodies

14 Publications Citing Use of MCE α-Vitamin E

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

α-Vitamin E Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

α-Vitamin E Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report